Acelyrin, Inc. (SLRN)
Largest Insider Buys in Sector
SLRN Stock Price History Chart
SLRN Stock Performance
About Acelyrin, Inc.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Insider Activity of Acelyrin, Inc.
Over the last 12 months, insiders at Acelyrin, Inc. have bought $0 and sold $7 worth of Acelyrin, Inc. stock.
On average, over the past 5 years, insiders at Acelyrin, Inc. have bought $23.72M and sold $39,598 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,250,000 shares for transaction amount of $22.5M was made by Westlake BioPartners Fund II, L.P. (10 percent owner) on 2023‑05‑09.
List of Insider Buy and Sell Transactions, Acelyrin, Inc.
| 2024-07-17 | Sale | director | 1 <0.0001% | $6.86 | $7 | -29.96% | ||
| 2024-01-02 | Sale | Chief Executive Officer | 10,691 0.0173% | $7.41 | $79,188 | -36.52% | ||
| 2023-05-09 | 10 percent owner | 1.25M 4.929% | $18.00 | $22.5M | -63.02% | |||
| 2023-05-09 | director | 50,000 0.1972% | $18.00 | $900,000 | -63.02% | |||
| 2023-05-09 | director | 15,000 0.0591% | $18.00 | $270,000 | -63.02% | |||
| 2023-05-09 | director | 3,000 0.0118% | $18.00 | $54,000 | -63.02% |